切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2020, Vol. 14 ›› Issue (12) : 1013 -1016. doi: 10.3877/cma.j.issn.1674-0785.2020.12.012

所属专题: 文献

综述

肝癌磁共振分子成像和成像靶点的研究进展
杜平杰1, 李杨1,()   
  1. 1. 637000 四川南充,川北医学院附属医院放射科
  • 收稿日期:2020-03-20 出版日期:2020-12-15
  • 通信作者: 李杨
  • 基金资助:
    四川省教育厅重点项目(17ZA0186); 南充市市校合作科研专项基金项目(NSMC20170431); 川北医学院博士科研启动基金项目(CBY15-QD11)

Magnetic resonance molecular imaging and imaging targets of hepatocellular carcinoma

Pingjie Du1, Yang Li1,()   

  1. 1. Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China
  • Received:2020-03-20 Published:2020-12-15
  • Corresponding author: Yang Li
引用本文:

杜平杰, 李杨. 肝癌磁共振分子成像和成像靶点的研究进展[J/OL]. 中华临床医师杂志(电子版), 2020, 14(12): 1013-1016.

Pingjie Du, Yang Li. Magnetic resonance molecular imaging and imaging targets of hepatocellular carcinoma[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(12): 1013-1016.

肝细胞癌是病死率高的恶性肿瘤之一。医学影像成像在肝癌的筛查和诊断中具有重要的临床意义。磁共振分子成像是一种具有广阔应用前景的重要诊断工具。本文介绍了分子成像的基本定义,并讨论了肝细胞癌磁共振成像的相关靶点。

Hepatocellular carcinoma (HCC) is a malignant tumor with high mortality. Medical imaging has an important role in the screening and diagnosis of HCC. Magnetic resonance molecular imaging is an important diagnostic tool with broad application prospects. This article describes the basic definition of molecular imaging and discusses the relevant targets for magnetic resonance imaging of HCC.

1
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2
陈万青, 崔富强, 樊春笋, 等. 中国肝癌一级预防专家共识 (2018) [J]. 临床肝胆病杂志, 2018, 34(10): 2090-2097.
3
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J]. Lancet, 2018, 391(10125): 1023-1075.
4
Kierans AS, Kang SK, Rosenkrantz AB. The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: A Meta-Analysis [J]. Radiology, 2016, 278(1): 82-94.
5
Anderson CJ, Lewis JS. Current status and future challenges for molecular imaging [J]. Philos Trans A Math Phys Eng Sci, 2017, 375(2107): 20170023.
6
James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications [J]. Physiol Rev, 2012, 92(2): 897-965.
7
Liang G, Nguyen PK. Molecular probes for cardiovascular imaging [J]. J Nucl Cardiol, 2016, 23(4): 783-789.
8
Son J, Hwang SH, Park S, et al. Imaging features of hepatocellular carcinoma: quantitative and qualitative comparison between MRI-Enhanced with Gd-EOB-DTPA and Gd-DTPA [J]. Invest Radiol, 2019, 54(8): 494-499.
9
Guggenheim EJ, Rappoport JZ, Lynch I. Mechanisms for cellular uptake of nanosized clinical MRI contrast agents [J]. Nanotoxicology, 2020, 14(4): 504-532.
10
Vallabani N, Singh S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics [J]. 3 Biotech, 2018, 8(6): 279.
11
Najafabadi RE, Kazemipour N, Esmaeili A, et al. Quercetin prevents body weight loss due to the using of superparamagnetic iron oxide nanoparticles in rat [J]. Adv Biomed Res, 2018, 7: 8.
12
Ma X, Wang S, Hu L, et al. Imaging characteristics of USPIO nanoparticles (<5 nm) as MR contrast agent in vitro and in the liver of rats [J]. Contrast Media Mol Imaging, 2019, 2019: 3687537.
13
Chen W, Shen B, Sun X. Analysis of progress and challenges of EGFR-targeted molecular imaging in cancer with a focus on affibody molecules [J]. Mol Imaging, 2019, 18: 1330212303.
14
Bellissimo F, Pinzone MR, Cacopardo B, et al. Diagnostic and therapeutic management of hepatocellular carcinoma [J]. World J Gastroenterol, 2015, 21(42): 12003-12021.
15
宋吉慧. AFP靶向USPIO分子探针在肝癌特异性MR成像中的价值 [D]. 济南: 山东大学, 2012.
16
Li YW, Chen ZG, Zhao ZS, et al. Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma [J]. World J Gastroenterol, 2015, 21(14): 4275-4283.
17
Zhou F, Shang W, Yu X, et al. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment [J]. Med Res Rev, 2018, 38(2): 741-767.
18
El-Saadany S, El-Demerdash T, Helmy A, et al. Diagnostic value of glypican-3 for hepatocellular carcinomas [J]. Asian Pac J Cancer Prev, 2018, 19(3): 811-817.
19
Zhao M, Liu Z, Dong L, et al. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma [J]. Int J Nanomedicine, 2018, 13: 4433-4443.
20
Ma XH, Wang S, Liu SY, et al. Development and in vitro study of a bi-specific magnetic resonance imaging molecular probe for hepatocellular carcinoma [J]. World J Gastroenterol, 2019, 25(24): 3030-3043.
21
Atta MM, Atta HM, Gad MA, et al. Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients [J]. J Hepatocell Carcinoma, 2016, 3: 19-24.
22
潘奇, 罗春海, 马婉玲, 等. 血管内皮生长因子C靶向分子探针在肝细胞癌大鼠模型中的特异性磁共振成像及临床意义 [J]. 临床肝胆病杂志, 2018, 34(7): 1492-1496.
23
潘奇, 罗春海, 马婉玲, 等. VEGF-C靶向USPIO分子探针的构建及其对肝癌细胞HepG2分子成像的初步研究 [J]. 医学影像学杂志, 2018, 28(9): 1557-1560.
24
Hu Q, Wang XY, Kang LK, et al. RGD-targeted ultrasound contrast agent for longitudinal assessment of Hep-2 tumor angiogenesis in vivo [J]. PLoS One, 2016, 11(2): e149075.
25
赵荣荣, 韩明, 程鑫, 等. MR分子探针RGD-USPIO评价核苷组合对人肝癌细胞Bel-7402的作用 [J]. 中国医学影像技术, 2017, 33(8): 1163-1166.
26
Jia Z, Song L, Zang F, et al. Active-target T1-weighted MR imaging of tiny hepatic tumor via RGD modified ultra-small Fe3O4 nanoprobes [J]. Theranostics, 2016, 6(11): 1780-1791.
27
Sid V, Siow YL, Karmin O. Role of folate in nonalcoholic fatty liver disease [J]. Can J Physiol Pharmacol, 2017, 95(10): 1141-1148.
28
唐纳, 赵光明, 李征宇, 等. NP-DA-Dextra-FA靶向纳米分子探针对人肝癌细胞的体外磁共振成像研究 [J]. 磁共振成像, 2017, 8(8): 604-608.
29
Li L, Gao F, Jiang W, et al. Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging [J]. Drug Deliv, 2016, 23(5): 1726-1733.
30
Sanjai C, Kothan S, Gonil P, et al. Super-paramagnetic loaded nanoparticles based on biological macromolecules for in vivo targeted MR imaging [J]. Int J Biol Macromol, 2016, 86: 233-241.
[1] 项文静, 徐燕, 茹彤, 郑明明, 顾燕, 戴晨燕, 朱湘玉, 严陈晨. 神经学超声检查在产前诊断胼胝体异常中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 470-476.
[2] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[3] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[4] 高金红, 陈玉梅, 郭韵. 基于King互动达标理论的心理疏导在腹腔镜肝癌切除术患者的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 517-520.
[5] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[6] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[7] 胡宁宁, 赵延荣, 王栋, 王胜亮, 郭源. FMNL3与肝细胞癌肝移植受者预后的相关性研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 283-288.
[8] 王飞, 陈政, 余德才, 曹亚娟. 原发性肝癌合并门静脉高压症的微创手术治疗[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 306-310.
[9] 张敏, 朱建华, 缪雅芳, 郭锦荣. 菝葜皂苷元对肝癌HepG2细胞抑制作用的机制研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 328-335.
[10] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[11] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[12] 张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.
[13] 广东省护士协会介入护士分会, 广东省医师协会介入医师分会. 原发性肝癌低血糖患者护理规范管理专家共识[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 709-714.
[14] 韦巧玲, 黄妍, 赵昌, 宋庆峰, 陈祖毅, 黄莹, 蒙嫦, 黄靖. 肝癌微波消融术后中重度疼痛风险预测列线图模型构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 715-721.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?